Valpione, Sara
Mundra, Piyushkumar A.
Galvani, Elena
Campana, Luca G. http://orcid.org/0000-0002-8466-8459
Lorigan, Paul http://orcid.org/0000-0002-8875-2164
De Rosa, Francesco http://orcid.org/0000-0003-0511-1298
Gupta, Avinash
Weightman, John
Mills, Sarah
Dhomen, Nathalie
Marais, Richard http://orcid.org/0000-0001-7484-4183
Funding for this research was provided by:
Harry J. Lloyd Charitable Trust (Career Development Award)
Cancer Research UK (A27412, A22902)
Wellcome Trust (100282/Z/12/Z)
Article History
Received: 30 July 2020
Accepted: 9 June 2021
First Online: 2 July 2021
Change Date: 22 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-24897-w
Competing interests
: R.M. is an expert witness for Pfizer, and as a former Institute of Cancer Research (London) employee, he may benefit from commercialized programs. P.L. serves as a paid advisor/speaker for Bristol-Myers Squibb, Merck Sharp and Dohme, Roche, Novartis, Amgen, Pierre Fabre, Nektar, and Melagenix. P.L. reports travel support from Bristol-Myers Squibb and Merck Sharp and Dohme and receives research support from Bristol-Myers Squibb. A.G. received honoraria and consultancy fees from BMS and Novartis. L.G.C. served as a paid advisor for Igea. F.D.R. serves as a paid advisor for MSD and had travel support from BMS and Novartis and honoraria from BMS. Other authors declare no competing interests.